» Articles » PMID: 15341933

Studies on Adenosine A2a Receptor Antagonists: Comparison of Three Core Heterocycles

Overview
Specialty Biochemistry
Date 2004 Sep 3
PMID 15341933
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Piperazine and (R)-2-(aminomethyl)pyrrolidine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been shown to be potent and selective adenosine A(2a) receptor antagonists. We have replaced the triazolotriazine core structure with two different heterocyclic cores. One of these, the one deriving from [1,2,4]triazolo[1,5-c]pyrimidine, appears to be particularly effective and selected analogs from this series have been shown to be orally active in a mouse catalepsy model of Parkinson's disease.

Citing Articles

Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.

Federico S, Paoletta S, Cheong S, Pastorin G, Cacciari B, Stragliotto S J Med Chem. 2011; 54(3):877-89.

PMID: 21214204 PMC: 3578427. DOI: 10.1021/jm101349u.


Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process.

Pastorin G, Federico S, Paoletta S, Corradino M, Cateni F, Cacciari B Bioorg Med Chem. 2010; 18(7):2524-36.

PMID: 20304654 PMC: 3106415. DOI: 10.1016/j.bmc.2010.02.039.


Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N Naunyn Schmiedebergs Arch Pharmacol. 2007; 375(2):133-44.

PMID: 17310264 DOI: 10.1007/s00210-007-0135-0.


Progress in the pursuit of therapeutic adenosine receptor antagonists.

Moro S, Gao Z, Jacobson K, Spalluto G Med Res Rev. 2005; 26(2):131-59.

PMID: 16380972 PMC: 9194718. DOI: 10.1002/med.20048.